Posted by Michael Wonder on 03 Oct 2025
Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at a list price equal to the US launch price
22 September 2025 - Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride), in the UK in 2026.
Bristol Myers Squibb plans to launch this medicine at a UK list price equal to the US list price, to reflect the value of this medicine for patients and society.
Bristol Myers Squibb intends to submit a marketing authorisation application for xanomeline and trospium chloride to the MHRA later this year, via the International Recognition Procedure.
